Research Papers:

Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model

Liangyou Gu, Xin Ma, Lei Wang, Hongzhao Li, Luyao Chen, Xintao Li, Yu Zhang, Yongpeng Xie and Xu Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:52094-52103. https://doi.org/10.18632/oncotarget.10626

Metrics: PDF 1895 views  |   HTML 3371 views  |   ?  


Liangyou Gu1,*, Xin Ma1,*, Lei Wang1,*, Hongzhao Li1, Luyao Chen1, Xintao Li1, Yu Zhang1, Yongpeng Xie1,2 and Xu Zhang1

1Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, P.R. China

2School of Medicine, Nankai University, Tianjin, China

*These authors contributed equally to this work

Correspondence to:

Xu Zhang, email: xzhang@foxmail.com

Keywords: inflammation, metastatic renal cell carcinoma, prognosis, biomarker, nomogram

Received: January 29, 2016     Accepted: June 07, 2016     Published: July 16, 2016


Inflammation act as a crucial role in carcinogenesis and tumor progression. In this study, we aim to investigate the prognostic significance of systemic inflammatory biomarkers in metastatic renal cell carcinoma (mRCC) and develop a survival predictive model. One hundred and sixty-one mRCC patients who had undergone cytoreductive nephrectomy were enrolled from January 2006 to December 2013. We created a systemic inflammation response index (SIRI) basing on pretreatment hemoglobin and lymphocyte to monocyte ratio (LMR), and evaluated its associations with overall survival (OS) and clinicopathological features. Pretreatment hemoglobin and LMR both remained as independent factors adjusted for other markers of systemic inflammation responses and conventional clinicopathological parameters. A high SIRI seems to be an independent prognosis predictor of worse OS and was significantly correlated with aggressive tumor behaviors. Inclusion of the SIRI into a prognostic model including Fuhrman grade, histology, tumor necrosis and targeted therapy established a nomogram, which accurately predicted 1-year survival for mRCC patients. The SIRI seems to be a prognostic biomarker in mRCC patients. The proposed nomogram can be applied to predict OS of patients with mRCC after nephrectomy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10626